Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to ...
45m
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Q4 2025 revenues of $112M, +46% vs. Q4 2024Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 ...
Confident in outlook, guiding to mid-single digit sales growth for 2026 and beyond. Strong financial position, with £350m share buyback well underway. LONDON, Feb. 27, 2026 /PRNewswire/ -- Financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results